Teva Pharmaceutical Industries Limited Announces Approval of Generic Protonix(R) Delayed Release Tablets, 20 mg and 40 mg

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company’s Abbreviated New Drug Application (ANDA) to market its generic version of Wyeth’s Protonix® (Pantoprazole Sodium) Delayed Release (DR) Tablets, 20 mg and 40 mg.

MORE ON THIS TOPIC